Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 10/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 3/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30039522 | 1.00 | RIPK1 (0.41) | RIPK1TGM2DDB1CRBNANPEP | |
| SCHEMBL15964688 | 1.00 | RIPK1 (0.41) | RIPK1TGM2DDB1CRBNANPEP | |
| SCHEMBL15964533 | 1.00 | RIPK1 (0.41) | RIPK1TGM2DDB1CRBNANPEP | |
| SCHEMBL23008858 | 0.85 | RIPK1 (0.35) | RIPK1CRBNANPEPSRD5A1 | |
| SCHEMBL15964687 | 0.85 | RIPK1 (0.32) | RIPK1DDB1CRBNANPEPSRD5A1 | |
| SCHEMBL15964534 | 0.85 | RIPK1 (0.32) | RIPK1DDB1CRBNANPEPSRD5A1 | |
| Pidolic Acid SCHEMBL20483433 | 0.84 | RIPK1 (0.39) | RIPK1DDB1CRBN | |
| SCHEMBL15964668 | 0.81 | RIPK1 (0.41) | RIPK1TGM2DDB1CRBN | |
| SCHEMBL22737132 | 0.81 | RIPK1 (0.32) | RIPK1TGM2 | |
| SCHEMBL29467170 | 0.81 | RIPK1 (0.41) | RIPK1TGM2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365695-B2 | Fused ring heteroaryl compounds as RIPK1 inhibitors | BISICHEM CO., LTD. (KR) | 2025-07-22 | — | — | US | disclosed |
| EP-4065565-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | Board of Regents, The University of Texas System (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-114206861-A | Fused heteroaryl compounds useful as RIPK1 inhibitors | 比西切姆有限公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365695-B2 | Fused ring heteroaryl compounds as RIPK1 inhibitors | RIPK1, RIPK3, RIPK4 | RIPK1 1/4885TGM2 3701/4885DDB1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.